Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Combination chemotherapy for human immunodeficiency virus-1

D J Manion1, M S Hirsch

  • 1Infectious Disease Unit, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA.

The American Journal of Medicine
|May 19, 1997
PubMed
Summary

Combination therapy offers synergistic benefits for treating diseases like HIV-1, reducing resistance and broadening effects. Studies support these additive interactions for effective clinical strategies, including postexposure prophylaxis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Progressive natural killer cell dysfunction in advanced-stage clear-cell renal cell carcinoma and association with clinical outcomes.

ESMO open·2025
Same author

SUSD2 expression in high-grade serous ovarian cancer correlates with increased patient survival and defective mesothelial clearance.

Oncogenesis·2016
Same author

PD-L1 expression in nonclear-cell renal cell carcinoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2014
Same author

FOXO3a loss is a frequent early event in high-grade pelvic serous carcinogenesis.

Oncogene·2013
Same author

Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis.

Oncogene·2009
Same author

Biomarker-assisted diagnosis of ovarian, cervical and pulmonary small cell carcinomas: the role of TTF-1, WT-1 and HPV analysis.

Histopathology·2007

Area of Science:

  • Virology
  • Pharmacology
  • Infectious Diseases

Background:

  • Combination therapy is increasingly vital for treating neoplastic and infectious diseases.
  • Human immunodeficiency virus (HIV)-1 infections are a primary focus for combination treatment strategies.

Purpose of the Study:

  • To review the advantages and potential interactions of combination therapy.
  • To examine the use of combination agents in healthcare worker postexposure prophylaxis.

Main Methods:

  • Review of in vitro and in vivo studies on combination drug effects.
  • Analysis of additive-to-synergistic antiviral interactions.
  • Evaluation of resistance emergence and coverage.

Main Results:

Related Experiment Videos

  • Combination therapies can yield additive-to-synergistic antiviral effects.
  • These approaches can decrease the emergence of resistant viruses.
  • Broadened efficacy across cell types and tissue reservoirs is achievable.

    • Conclusions:

    • Combination drug interactions range from synergy to antagonism.
    • Evidence supports the clinical use of combination strategies.
    • Combination therapy is relevant for postexposure prophylaxis protocols.